WO1998032429A3 - P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing - Google Patents

P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing Download PDF

Info

Publication number
WO1998032429A3
WO1998032429A3 PCT/GB1998/000205 GB9800205W WO9832429A3 WO 1998032429 A3 WO1998032429 A3 WO 1998032429A3 GB 9800205 W GB9800205 W GB 9800205W WO 9832429 A3 WO9832429 A3 WO 9832429A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin conditions
antagonists
wound healing
modulators
improvement
Prior art date
Application number
PCT/GB1998/000205
Other languages
French (fr)
Other versions
WO1998032429A2 (en
Inventor
James Anthony Gallagher
Wayne Barry Bowler
Original Assignee
Univ Liverpool
James Anthony Gallagher
Wayne Barry Bowler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liverpool, James Anthony Gallagher, Wayne Barry Bowler filed Critical Univ Liverpool
Priority to AU56747/98A priority Critical patent/AU5674798A/en
Publication of WO1998032429A2 publication Critical patent/WO1998032429A2/en
Publication of WO1998032429A3 publication Critical patent/WO1998032429A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to P2 agonists and antagonists or a compound which will stimulate or inhibit endogenous adenosine triphosphate (ATP) production, and more particularly to novel medical uses for same. More particularly still it relates to treating skin conditions characterised by hyperproliferation of keratinocytes, including for example, keloid formation, dermatitis and psoriasis or enhancing wound healing. The invention provides the use of an agonist or antagonist of a type P2-receptor or a compound which will stimulate or inhibit adenosine triphosphate (ATP) production for the manufacture of a medicament for treating wounds or skin conditions characterised by hyperproliferation of keratinocytes or acanthosis. It also provides a pharmaceutical composition comprising a growth factor, a pharmaceutically acceptable carrier and either an agonist of a P2Y receptor or a compound which will stimulate adenosine triphosphate (ATP) production.
PCT/GB1998/000205 1997-01-23 1998-01-23 P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing WO1998032429A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56747/98A AU5674798A (en) 1997-01-23 1998-01-23 P2 receptor agonists, antagonists and modulators of endogenous atp release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9701374.2A GB9701374D0 (en) 1997-01-23 1997-01-23 Purinergic agonists and antagonists
GB9701374.2 1997-01-23

Publications (2)

Publication Number Publication Date
WO1998032429A2 WO1998032429A2 (en) 1998-07-30
WO1998032429A3 true WO1998032429A3 (en) 1999-04-01

Family

ID=10806475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000205 WO1998032429A2 (en) 1997-01-23 1998-01-23 P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing

Country Status (3)

Country Link
AU (1) AU5674798A (en)
GB (1) GB9701374D0 (en)
WO (1) WO1998032429A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0120704D0 (en) * 2000-09-01 2001-10-17 Glaxo Group Ltd Polypeptide
FR2826278B1 (en) * 2001-06-20 2005-03-25 Lipha USE OF ANTIDIABETIC AGENTS FOR MANUFACTURING A MEDICAMENT HAVING A HEALING EFFECT
DE60216453T2 (en) * 2001-06-20 2007-09-20 Merck Santé USE OF ANTI-DIABETICS FOR THE PREPARATION OF A TREATMENT-DRIVING MEDICAMENT
WO2003084485A1 (en) 2002-04-09 2003-10-16 Otsuka Pharmaceutical Co., Ltd. Composition for cell proliferation
US20070032456A1 (en) * 2003-03-27 2007-02-08 Friesen Albert D Modulation of cell death
BRPI0415229A (en) 2003-10-08 2006-12-05 Otsuka Pharma Co Ltd composition for promotion of collagen production
JP5092400B2 (en) * 2004-06-28 2012-12-05 味の素株式会社 Nutritional composition and composition for preventing or improving digestive tract function deterioration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03236320A (en) * 1990-02-09 1991-10-22 Kobayashi Kose Co Ltd Skin drug for external use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03236320A (en) * 1990-02-09 1991-10-22 Kobayashi Kose Co Ltd Skin drug for external use

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
BHAGWAT, S.S. ET AL: "P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 3, 1997, pages 183 - 193, XP002089239 *
BORISENKO, K.K. ET AL: "Pyridoxal-5-phosphate in treatment of disseminated dermatoses", VESTNIK DERMATOLOGII I VENEROLOGII, vol. 9, 1977, pages 68 - 71, XP002089235 *
CHANG, K. ET AL: "Molecular cloning and functional analysis of a novel p2 nucleotide receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 44, 3 November 1995 (1995-11-03), pages 26152 - 58, XP002089240 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002089244 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002089245 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002089246 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002089247 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002089248 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002089249 *
DATABASE DISSERTATION ABSTRACTS 1995, GAGLIARDI, A.: "Inhibition of angiogenesis by Suramin and its analogues (neovascularization, tumor vasculature)", XP002089243 *
DATABASE WPI Week 9148, Derwent World Patents Index; AN 91-350854, XP002074027 *
HUANG, N. ET AL: "Extracellular ATP is a mitogen for 3T3, 3T6 and A431 cells and acts synergistically with other growth factors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 86, October 1989 (1989-10-01), pages 7904 - 7908, XP002074023 *
INOUE, K. ET AL: "Antagonism by reactive blue 2 but not by brilliant blue G of extracellular ATP-evoked responses in PC12 phaeochromocytoma cells", BRITISH JOURNAL OF PHARMACOLOGY, vol. 102, 1991, pages 851 - 854, XP002089242 *
JOSEPH, J. ET AL: "Exogenous ATP causes the contraction of intact fibroblasts in vitro", EXPERIMENTAL CELL RESEARCH, vol. 176, no. 1, 1988, pages 1-12, XP002074024 *
KOROTKII, N.G. ET AL: "Experience of treating chronically relapsing dermatoses with pridoxal phosphate", VESTNIK DERMATOILOGII I VENEROLOGII, vol. 2, 1982, pages 45 - 48, XP002089236 *
KOVLER, M.A. ET AL: "Pyridoxal phosphate the coenzyme form of vitamin B-6", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 13, no. 10, 1979, pages 112 - 116 *
LAMBRECHT, G.: "Design and pharmacology of selective P2-purinoceptor antagonists", JOURNAL OF AUTONOMIC PHYSIOLOGY, vol. 16, no. 6, 1996, pages 341 - 344, XP002089238 *
NOBLES, M. ET AL: "Characteristics of nucleotide receptors that cause elevation of cytoplasmic calcium in immortalized rat brain endothelial cells (RBE4) and in primary cultures", BRITISH JOURNAL OF PHARMACOLOGY, vol. 115, no. 7, 1995, pages 1245 - 1252, XP002089237 *
OLISOVA, M.O.: "Use of endogenic photosensitizers (chromophores) to increase the efficacy of selective phototherapy in psoriatic patients. Part II: Therapeutic efficacy", VESTNIK DERMATOLOGII I VENEROLOGII, vol. 0, no. 3, 1995, pages 4 - 6 *
OLISOVA, M.O.: "Use of endogenic photosensitizers (chromophores) to increase the efficacy of selective phototherapy of psoriatic patients", VESTNIK DERMATOLOGII I VENEROLOGII, vol. 0, no. 5, 1995, pages 7 - 9 *
OLISOVA, M.O.: "Use of endogenous photosensitizers (chromophores) to improve the efficacy of selective phototherapy of psoriasis patients. Communication I. Efficacy and mechanisms of action.", VESTNIK DERMATOLOGII I VENEROLOGII, vol. 0, no. 6, 1994, pages 10 - 12 *
PILLAI, S. ET AL: "Adenosine triphosphate stimulates phosphoinositide metabolism, mobilizes intracellular calcium and inhibits terminal differentiation of human epidermal keratinocytes", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 90, no. 1, July 1992 (1992-07-01), pages 42 - 51, XP002074020 *
SHARPE, G.R. ET AL: "Regulation of keratinocyte proliferation by extracellular nucleotides acting at p2y2 receptors", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 110, no. 4, April 1998 (1998-04-01), pages 545, XP002074026 *
SHAVER, S.R. ET AL: "4-Substituted uridine 5'-triphosphates as agonists of the p2y2 purinergic receptor", NUCLEOSIDES AND NUCLEOTIDES, vol. 16, no. 7-9, 1997, pages 1099 - 1102, XP002074025 *
SUTER, M.M. ET AL: "Extracellular ATP and some of its analogs induce transient rises in cytosolic free calcium in individual canine keratinocytes", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 97, no. 2, August 1991 (1991-08-01), pages 223-9, XP002074021 *
TISHCHENKO, A.L.: "Alcohol abuse and pyridoxine metabolism in patients with psoriasis: therapeutic aspects", VESTNIK DERMATOLOGII I VENEROLOGII, vol. 0, no. 3, 1997, pages 36 - 38 *
TISHCHENKO, A.L.: "Effect of solar radiatin on blood pyridoxine levels in patients with various forms of dermatosis in Africa", VESTNIK DERMATOLOGII I VENEROLOGII, vol. 0, no. 5, 1997, pages 35 - 36 *
WANG, D. ET AL: "Extracellular ATP shows synergistic enhancement of DNA synthesis when combined with agents that are active in wound healing or as neurotransmitters", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 166, no. 1, January 1990 (1990-01-01), pages 251 - 258, XP002074022 *
YAMAGUCHI, M. ET AL: "Enhancement of differentiation induction of mouse myelomonocytic leukaemic cells by extracellular ATP", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 159, no. 3, 1994, pages 441 - 449, XP002089241 *

Also Published As

Publication number Publication date
WO1998032429A2 (en) 1998-07-30
GB9701374D0 (en) 1997-03-12
AU5674798A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
HUP0203870A2 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1194421A4 (en) Selective npy (y5) antagonists
BR9813373A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient
NZ328898A (en) Sustained release formulation containing collagen and glycosaminoglycan additives
ES2096312T3 (en) QUINUCLIDINE DERIVATIVE AS ANTAGONIST OF THE SUBSTANCE P.
CA2246839A1 (en) Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
MY125821A (en) Pharmaceutical composition of topiramate
AP1760A (en) Platinum derivative pharmaceutical formulations.
MXPA03001518A (en) Composition and method for inhibiting platelet aggregation.
BR9714082A (en) Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
BR0312648A (en) Process for preparing certain pyrrole triazine compounds
WO2003048164A3 (en) Adenosine a2a receptor antagonists
UA35567C2 (en) Pharmaceutical preparation for treating patients with coagulation impairment, method for treatment, method for pharmaceutical manufacturing
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
PT1140031E (en) PHARMACEUTICAL PREPARATION OF CONTROLLED LIBERATION WITH TILIDINE MESYLATE AS AN ACTIVE SUBSTANCE
AU2108500A (en) Galenic formulation containing biotin
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
WO1998032429A3 (en) P2 receptor agonists, antagonists and modulators of endogenous atp release for the treatment of skin conditions and the improvement of wound healing
GB2352972A (en) Use of dexmedetomidine for icu sedation
AU2001263130A1 (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
TW200501963A (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
AR013163A1 (en) USE OF COMPOSITIONS CONTAINING DICHLOROPHENIL IMIDAZOLDIOXOLANE FOR THE PREPARATION OF A MEDICATION TO TREAT SEBORRHEIC DERMATITIS, DANDRUFF, PSORIASIS AND ACNE, PROPERLY SAID COMPOSITIONS, AND A MANUFACTURING ARTICLE CONTAINING SUCH COMPOSITION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998531731

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase